teriflunomide
Selected indexed studies
- Ofatumumab versus Teriflunomide in Multiple Sclerosis. (N Engl J Med, 2020) [PMID:32757523]
- Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. (N Engl J Med, 2022) [PMID:36001711]
- Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis. (N Engl J Med, 2025) [PMID:40202623]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ofatumumab versus Teriflunomide in Multiple Sclerosis. (2020) pubmed
- Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. (2022) pubmed
- Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. (2021) pubmed
- Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis. (2025) pubmed
- Teriflunomide: Pediatric First Approval. (2021) pubmed
- Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial. (2023) pubmed
- Teriflunomide: A Review in Relapsing-Remitting Multiple Sclerosis. (2019) pubmed
- Teriflunomide: an oral therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis. (2023) pubmed
- Teriflunomide for multiple sclerosis. (2016) pubmed
- Teriflunomide vs injectable disease modifying therapies for relapsing forms of MS. (2020) pubmed